Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.

Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.
复制标题

DOI:
10.1136/jnnp-2017-316625
复制
发表时间:
2018-05
期刊:
Journal of neurology, neurosurgery, and psychiatry
影响因子:
--
通讯作者:
Aoki M
Aoki M
中科院分区:
其他
文献类型:
--
作者:
Imai T;Utsugisawa K;Murai H;Tsuda E;Nagane Y;Suzuki Y;Minami N;Uzawa A;Kawaguchi N;Masuda M;Konno S;Suzuki H;Akaishi T;Aoki M

文献摘要

参考文献

被引文献

相似文献

We examined the correlation between the dosing regimen of oral prednisolone (PSL) and the achievement of minimal manifestation status or better on PSL ≤5 mg/day lasting >6 months (the treatment target) in patients with generalised myasthenia gravis (MG). We classified 590 patients with generalised MG into high-dose (n=237), intermediate-dose (n=187) and low-dose (n=166) groups based on the oral PSL dosing regimen, and compared the clinical characteristics, previous treatments other than PSL and prognosis between three groups. The effect of oral PSL dosing regimen on the achievement of the treatment target was followed for 3 years of treatment. To achieve the treatment target, ORs for low-dose versus high-dose regimen were 10.4 (P<0.0001) after 1 year of treatment, 2.75 (P=0.007) after 2 years and 1.86 (P=0.15) after 3 years; and those for low-dose versus intermediate-dose regimen were 13.4 (P<0.0001) after 1 year, 3.99 (P=0.0003) after 2 years and 4.92 (P=0.0004) after 3 years. Early combined use of fast-acting treatment (OR: 2.19 after 2 years, P=0.02; OR: 2.11 after 3 years, P=0.04) or calcineurin inhibitors (OR: 2.09 after 2 years, P=0.03; OR: 2.36 after 3 years, P=0.02) was associated positively with achievement of treatment target. A low-dose PSL regimen with early combination of other treatment options may ensure earlier achievement of the treatment target in generalised MG.
DOI: 10.1212/wnl.0000000000002790
发表时间: 2016-07-26
期刊: Neurology
影响因子: 9.9
作者:
Sanders DB;Wolfe GI;Benatar M;Evoli A;Gilhus NE;Illa I;Kuntz N;Massey JM;Melms A;Murai H;Nicolle M;Palace J;Richman DP;Verschuuren J;Narayanaswami P
通讯作者: Narayanaswami P
DOI: 10.3109/08916930903518107
发表时间: 2010-08-01
期刊: AUTOIMMUNITY
影响因子: 3.5
作者:
Sanders, Donald B.;Evoli, Amelia
通讯作者: Evoli, Amelia
DOI: 10.1111/j.1600-0404.1998.tb05968.x
发表时间: 1998-06-01
影响因子: 3.5
作者:
Lindberg, C;Andersen, O;Lefvert, AK
通讯作者: Lefvert, AK
DOI: 10.1002/mus.25397
发表时间: 2017-06
期刊: Muscle & nerve
影响因子: 3.4
作者:
Utsugisawa K;Nagane Y;Akaishi T;Suzuki Y;Imai T;Tsuda E;Minami N;Uzawa A;Kawaguchi N;Masuda M;Konno S;Suzuki H;Murai H;Aoki M
通讯作者: Aoki M
DOI: 10.1016/j.clinph.2011.07.044
发表时间: 2012-03-01
影响因子: 4.7
作者:
Kokubun, Norito;Sonoo, Masahiro;Arimura, Kimiyoshi
通讯作者: Arimura, Kimiyoshi